bcbs massachusetts glp 1 coverage Blue Cross Blue Shield plans reverse course on GLP-1 What to Know About the

Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes

[DOI] [PubMed] [Google Scholar] 618.Nikolaidis L.A., Doverspike A., Hentosz T., Zourelias L., Shen Y.T., Elahi D

418,419 Although research on the pathophysiological mechanisms of DN covers multiple aspects, several pathways remain poorly understood, and the clinical application of treatment strategies remains limited

Glucagon-like peptide 1 receptor agonists (GLP-1s) are on track to become one of the largest drug classes in history, driven by demand for weight loss alternatives and the potential of GLP-1s to treat a range of conditions such as diabetes, cardiovascular risk, liver disease, and dementia

Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that causes sudden blindness, has been linked to GLP-1 use